ArticleFrontiers in oncology2026
Preoperative HALP and LMR predict disease-free survival in stage III colon cancer and enable nomogram-based risk stratification.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- V7-DiVA: a feature-based Deep MIL colorectal whole-slide histopathology research platform with blinded external image-input validation.Journal of translational medicine · 2026Article
- The role of the preoperative HALP score in predicting pathological T and N categories in colon cancer: a single-center retrospective study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer remains a major cause of cancer-related mortality worldwide. Despite curative resection and standard adjuvant chemotherapy, patients with stage III colon cancer remain at considerable risk of recurrence, with marked survival heterogeneity within the same pathological stage. Systemic inflammatory and immunonutritional biomarkers, including the hemoglobin-albumin-lymphocyte-platelet (HALP) score, systemic immune-inflammation index (SII), and lymphocyte-to-monocyte ratio (LMR), may reflect host-tumor interactions. However, their combined diagnostic and prognostic value in stage III colon cancer patients have not been fully established. Methods: This retrospective study included 210 patients with stage III colon cancer who underwent curative resection and 220 comparable patients with benign colonic lesions. Diagnostic performance was assessed using receiver operating characteristic analysis and logistic regression. Patients with stage III disease were randomly assigned to training and validation cohorts (7:3). Independent predictors of disease-free survival (DFS) were identified using Cox regression, and a nomogram was constructed and internally validated using the concordance index (C-index), time-dependent ROC analysis, calibration curves, and decision curve analysis. Results: HALP, SII, and LMR showed moderate discrimination for malignancy, with AUC of 0.773, 0.758, and 0.739, respectively. Multivariable analysis identified HALP (HR = 0.384, 95% CI: 0.225-0.655), LMR (HR = 0.483, 95% CI: 0.286-0.815), tumor stage (HR = 2.435, 95% CI: 1.432-4.140), and chemotherapy cycles (HR = 0.380, 95% CI: 0.223-0.647) as independent predictors of DFS. The nomogram demonstrated good discrimination (C-index 0.759 and 0.743 in the training and validation set) with satisfactory calibration and clinical net benefit. Conclusion: Preoperative HALP and LMR independently predict DFS in stage III colon cancer. A nomogram integrating inflammatory biomarkers with clinicopathological variables enables individualized recurrence risk estimation and may inform postoperative risk-adapted management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.